Altered bone mass and turnover in female patients with adrenal incidentaloma: The effect of subclinical hypercortisolism

Research output: Contribution to journalArticle

Abstract

The strategy of treatment for patients with adrenal incidentalomas (AI) may depend upon the presence of hormonal hypersecretion. Although alterations of bone turnover have been recently reported, data on bone mineral density (BMD) are not available in AI patients. We evaluated bone turnover and BMD in 32 female AI patients and 64 matched controls. Spinal and femoral BMD were similar in patients and controls. Serum bone GLA protein (6.8 ± 3.5 vs. 8.8 ± 3.2 ng/mL; P <0.005) and PTH (48.8 ± 15.1 vs. 37.2 ± 10.9 pg/mL; P <0.0001) were different in patients and controls. Patients were then subdivided into 2 groups: with (n = 8; group A) or without (n = 24; group B) subclinical hypercortisolism. PTH was higher (P <0.05) in group A than in group B and in both groups than in controls (57.1 ± 13.6, 46.0 ± 14.8, and 37.2 ± 10.9 pg/mL, respectively), and bone GLA protein was lower in group A than in group B and controls (3.8 ± 2.3, 7.5 ± 3.1, and 8.8 ± 3.2 ng/mL, respectively; P <0.05). Serum type I cross-linked C telopeptide and fasting urinary deoxypyridinoline/creatinine were not different in the three groups. BMD at each site was lower (P <0.05) in group A than in group B and controls. Bone mass and metabolism are altered in AI patients with subclinical hypercortisolism and should be taken into account, therefore, when addressing the treatment of choice for these patients.

Original languageEnglish
Pages (from-to)2381-2385
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume84
Issue number7
Publication statusPublished - 1999

Fingerprint

Cushing Syndrome
Bone Remodeling
Bone
Bone Density
Minerals
Bone and Bones
Control Groups
Adrenal incidentaloma
Thigh
Serum
Metabolism
Fasting
Creatinine
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{8203ed23448d4a5b96fd9bcd8884573a,
title = "Altered bone mass and turnover in female patients with adrenal incidentaloma: The effect of subclinical hypercortisolism",
abstract = "The strategy of treatment for patients with adrenal incidentalomas (AI) may depend upon the presence of hormonal hypersecretion. Although alterations of bone turnover have been recently reported, data on bone mineral density (BMD) are not available in AI patients. We evaluated bone turnover and BMD in 32 female AI patients and 64 matched controls. Spinal and femoral BMD were similar in patients and controls. Serum bone GLA protein (6.8 ± 3.5 vs. 8.8 ± 3.2 ng/mL; P <0.005) and PTH (48.8 ± 15.1 vs. 37.2 ± 10.9 pg/mL; P <0.0001) were different in patients and controls. Patients were then subdivided into 2 groups: with (n = 8; group A) or without (n = 24; group B) subclinical hypercortisolism. PTH was higher (P <0.05) in group A than in group B and in both groups than in controls (57.1 ± 13.6, 46.0 ± 14.8, and 37.2 ± 10.9 pg/mL, respectively), and bone GLA protein was lower in group A than in group B and controls (3.8 ± 2.3, 7.5 ± 3.1, and 8.8 ± 3.2 ng/mL, respectively; P <0.05). Serum type I cross-linked C telopeptide and fasting urinary deoxypyridinoline/creatinine were not different in the three groups. BMD at each site was lower (P <0.05) in group A than in group B and controls. Bone mass and metabolism are altered in AI patients with subclinical hypercortisolism and should be taken into account, therefore, when addressing the treatment of choice for these patients.",
author = "Massimo Torlontano and I. Chiodini and M. Pileri and G. Guglielmi and M. Cammisa and S. Modoni and V. Carnevale and V. Trischitta and A. Scillitani",
year = "1999",
language = "English",
volume = "84",
pages = "2381--2385",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Altered bone mass and turnover in female patients with adrenal incidentaloma

T2 - The effect of subclinical hypercortisolism

AU - Torlontano, Massimo

AU - Chiodini, I.

AU - Pileri, M.

AU - Guglielmi, G.

AU - Cammisa, M.

AU - Modoni, S.

AU - Carnevale, V.

AU - Trischitta, V.

AU - Scillitani, A.

PY - 1999

Y1 - 1999

N2 - The strategy of treatment for patients with adrenal incidentalomas (AI) may depend upon the presence of hormonal hypersecretion. Although alterations of bone turnover have been recently reported, data on bone mineral density (BMD) are not available in AI patients. We evaluated bone turnover and BMD in 32 female AI patients and 64 matched controls. Spinal and femoral BMD were similar in patients and controls. Serum bone GLA protein (6.8 ± 3.5 vs. 8.8 ± 3.2 ng/mL; P <0.005) and PTH (48.8 ± 15.1 vs. 37.2 ± 10.9 pg/mL; P <0.0001) were different in patients and controls. Patients were then subdivided into 2 groups: with (n = 8; group A) or without (n = 24; group B) subclinical hypercortisolism. PTH was higher (P <0.05) in group A than in group B and in both groups than in controls (57.1 ± 13.6, 46.0 ± 14.8, and 37.2 ± 10.9 pg/mL, respectively), and bone GLA protein was lower in group A than in group B and controls (3.8 ± 2.3, 7.5 ± 3.1, and 8.8 ± 3.2 ng/mL, respectively; P <0.05). Serum type I cross-linked C telopeptide and fasting urinary deoxypyridinoline/creatinine were not different in the three groups. BMD at each site was lower (P <0.05) in group A than in group B and controls. Bone mass and metabolism are altered in AI patients with subclinical hypercortisolism and should be taken into account, therefore, when addressing the treatment of choice for these patients.

AB - The strategy of treatment for patients with adrenal incidentalomas (AI) may depend upon the presence of hormonal hypersecretion. Although alterations of bone turnover have been recently reported, data on bone mineral density (BMD) are not available in AI patients. We evaluated bone turnover and BMD in 32 female AI patients and 64 matched controls. Spinal and femoral BMD were similar in patients and controls. Serum bone GLA protein (6.8 ± 3.5 vs. 8.8 ± 3.2 ng/mL; P <0.005) and PTH (48.8 ± 15.1 vs. 37.2 ± 10.9 pg/mL; P <0.0001) were different in patients and controls. Patients were then subdivided into 2 groups: with (n = 8; group A) or without (n = 24; group B) subclinical hypercortisolism. PTH was higher (P <0.05) in group A than in group B and in both groups than in controls (57.1 ± 13.6, 46.0 ± 14.8, and 37.2 ± 10.9 pg/mL, respectively), and bone GLA protein was lower in group A than in group B and controls (3.8 ± 2.3, 7.5 ± 3.1, and 8.8 ± 3.2 ng/mL, respectively; P <0.05). Serum type I cross-linked C telopeptide and fasting urinary deoxypyridinoline/creatinine were not different in the three groups. BMD at each site was lower (P <0.05) in group A than in group B and controls. Bone mass and metabolism are altered in AI patients with subclinical hypercortisolism and should be taken into account, therefore, when addressing the treatment of choice for these patients.

UR - http://www.scopus.com/inward/record.url?scp=0033305756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033305756&partnerID=8YFLogxK

M3 - Article

C2 - 10404807

AN - SCOPUS:0033305756

VL - 84

SP - 2381

EP - 2385

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -